13/07/2013
Ban on anti-diabetes drug pioglitazone shocks doctors ........ The ban on pioglitazone (anti-diabetes drug) has come as a rude shock to doctors who have demanded the government conduct an investigation and trial before it is pulled out of the market.
The health ministry had recently banned pioglitazone, analgin (painkiller) and deanxit (an anti-depressant).
According to the health ministry, the ban was promulgated after the drugs showed adverse effects on users. Though the ban on analgin and deanxit have been justified by medical professionals, the ban on pioglitazone and its substitutes has taken many by surprise.
Dr Abhay A M***a, chief diabetologist, Ruby Hall Clinic, and director, Diabetes Care and Research Foundation, Pune, said pioglitazone is probably the most potent and effective oral drug option among the five available groups, sixth being the insulin. An estimated 30 lakh Indian diabetic population is likely to be on pioglitazone combinations, which is a cheap and effective drug that helps in preventing many diabetes-related complications in the long run. In Pune, there are around 5 lakh diabetic patients and nearly 10 per cent are on the drug, added M***a.
He said doctors are trained to prescribe drugs with caution by screening appropriate patient group. Raised sugar itself is a pro-cancerous state. If sugar is uncontrolled, it can lead to many cancers and diabetes-related complications. Even developed countries like US and UK have not banned the drug (where the research on pioglitazone takes place). US has even gone a step further and has approved pioglitazone along with a combination pill with alogliptin (even though the combination drugs are not approved in US), he added.
Pioglitazone is endorsed and recommended by all major guidelines of diabetes management — ADA (American diabetes association), EASD (Europe) and IDF (International diabetes Federation). Indian doctors follow the above guidelines while managing diabetes. The sudden stopping of pioglitazone will seriously disturb patient's blood sugars, as it is the only major insulin-sensitiser drug available.